2023-05-01 06:50:51 ET
- RadNet ( NASDAQ: RDNT ) said it received FDA clearance for the third-generation release of its Quantib Prostate 3.0 MRI artificial intelligence (AI) software.
- The software for MRI reading support was first introduced in the U.S., followed by a class IIb CE marking in Europe in 2021.
- Quantib Prostate 3.0 is an AI-based software which advances the MRI prostate reporting workflow and provides a suite of tools that improve reporting quality and speed, according to the company.
- RadNet said the FDA 510k special clearance has an upgrade to the latest Quantib Prostate 2.1 release. The upcoming release will include an improved prostate and sub-region segmentation algorithm, and automated drawing of the lesions on the PI-RADS sector map, among other things.
For further details see:
RadNet's AI-based Quantib Prostate 3.0 software gets FDA clearance